Presenilins Mediate Phosphatidylinositol 3-Kinase/AKT and ERK Activation via Select Signaling Receptors

**SELECTIVITY OF PS2 IN PLATELET-DERIVED GROWTH FACTOR SIGNALING**

Received for publication, January 24, 2005, and in revised form, June 8, 2005
Published, JBC Papers in Press, July 13, 2005, DOI 10.1074/jbc.M500833200

David E. Kang, Il Sang Yoon, Emanuela Repetto, Tracy Busse, Nader Yermian, Listya Ie, and Edward H. Koo

From the Department of Neurosciences, University of California, San Diego, La Jolla, California 92039

The Alzheimer’s disease-linked genes, PS1 and PS2, are required for intramembrane proteolysis of multiple type I proteins, including Notch and amyloid precursor protein. In addition, it has been documented that PS1 positively regulates, whereas PS1 familial Alzheimer disease mutations suppress, phosphatidylinositol 3-kinase (PI3K)/Akt activation, a pathway known to inactivate glycogen synthase kinase-3 and reduce tau phosphorylation. In this study, we show that the loss of presenilins not only inhibits PI3K/Akt signaling and increases tau phosphorylation but also suppresses the MEK/ERK pathway. The deficits in Akt and ERK activation in cells deficient in both PS1 and PS2 (PS/−/−) are evident after serum withdrawal and stimulation with fetal bovine serum or ligands of select receptor tyrosine kinases, platelet-derived growth factor receptor β (PDGFRβ) and PDGFRα, but not insulin-like growth factor-1R and epidermal growth factor receptor. The defects in PDGF signaling in PS/−/− cells are due to reduced expression of PDGF receptors. Whereas fetal bovine serum-induced Akt activation is reconstituted by both PS1 and PS2 in PS/−/− cells, PDGF signaling is selectively restored by PS2 but not PS1 and is dependent on the N-terminal fragment of PS2 but not γ-secretase activity or the hydrophilic loop of PS2. The rescue of PDGF receptor expression and activation by PS2 is facilitated by FHL2, a PS2-interacting transcriptional co-activator. Finally, we present evidence that PS1 mutations interfere with this PS2-mediated activity by reducing PS2 fragments. These findings highlight important roles of both presenilins in Akt and ERK signaling via select signaling receptors.

Mutations in two homologous presenilin genes, PS1 and PS2, account for the vast majority of early onset familial Alzheimer disease (FAD) (1, 2), whose pathology is virtually identical to sporadic AD characterized by deposition of βAmyloid and hyperphosphorylated tau inclusion in neurofibrillary tangles. The presenilins are polytopic proteins with 6–8 transmembrane domains that are found in high molecular weight complexes together with nicastrin, pen-2, and apol-1. These four proteins are required for the regulated intramembrane proteolysis (RIP or γ-secretase activity) of various substrates, including the amyloid precursor protein (APP) and Notch (3). Accordingly, null mice for any one of these components display embryonic lethality associated with severe malformations of the axial skeleton and cerebral hemorrhage, resembling that of Notch deficiency (3). As expected, this activity is conserved in Caenorhabditis elegans and Drosophila, where the presenilin complex functions to facilitate Notch signaling (4, 5).

All presenilin mutations associated with FAD favor the enhanced production of the pathogenic Aβ42 peptide, suggesting that this is the primary cause of familial cases of AD. Although the amyloid hypothesis is the leading model for AD pathogenesis, a number of concerns with this hypothesis have led many to suggest that non-amyloid-related cellular perturbations of presenilin mutations contribute to the disease phenotype. This is especially plausible in light of the recent observations that three separate PS1 mutations are associated with frontotemporal dementia, a neurodegenerative disorder characterized by tauopathy and without Aβ/amyloid pathology (6–8). The tau pathology in these cases may be explained in part by the role of presenilin in tau phosphorylation. For example, conditional ablation of both PS1 and PS2, but not either gene alone, in adult brain resulted in prominent hyperphosphorylation of tau that was associated with neuronal degeneration and severe learning and memory deficits (9, 10). In sum, these observations strongly suggest that presenilin dysfunctions can contribute to tau pathology and neurodegeneration independent of its effects on Aβ/amyloid pathology.

The manner in which presenilins could directly contribute to tauopathy and neurodegeneration is unknown. However, presenilins are multifunctional proteins. In addition to their roles in Aβ production and Notch proteolysis, presenilins have been shown to mediate other physiological activities in vitro and in vivo.

Alzheimer disease; APP, amyloid precursor protein; RTK, receptor tyrosine kinase; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; ERK, extracellular signal-regulated kinase; PI3K, phosphatidylinositol 3-kinase; CHAPS, 3-(3-cholamidopropyl)dimethylammonio-1-propanesulfonic acid; IGF, insulin-like growth factor; EGF, epidermal growth factor; PDGF, platelet-derived growth factor; PDGFR, PDGF receptor; DMEM, Dulbecco’s modified Eagle’s medium; PBS, fetal bovine serum; siRNA, small interfering RNA; RT, reverse transcription; CTF, C-terminal fragment; NTF, N-terminal fragment; CREB, cAMP-response element-binding protein; CBP, CREB-binding protein.
in vivo. First, a role for presenilins in the trafficking and maturation of select membrane proteins and/or intracellular vesicles has been shown, although the mechanisms of this activity are unclear (11–14). For example, Naruse et al. (13) demonstrated that the glycosylation, trafficking, and signaling of TrkB, a receptor tyrosine kinase (RTK) that signals through the phosphatidylinositol 3-kinase (PI3K)/Akt/glycogen synthase kinase-3 (GSK-3) and MEK/ERK pathways, are altered in PS1-deficient neurons. Second, the turnover of other membrane proteins, such as α-synuclein and telencephalin, is delayed by PS1 deficiency, and the molecules accumulate in large vacuolar structures resembling autophagosomes (12, 14).

Third, we previously demonstrated that presenilin negatively regulates the Wnt/β-catenin signaling pathway through facilitating the paired phosphorylation and degradation of β-catenin by acting as a scaffold upon which a priming kinase, GSK-3β, phosphorylates Ser33/37/41 of β-catenin (15, 16). In a different modality, several studies reported that PS1 and PS2 FAD mutations can also differentially modulate GSK-3 activity via PI3K/Akt signaling, a pathway that leads to GSK-3 inactivation and reduced tau phosphorylation (17–19). In this study, we investigated the mechanistic framework by which presenilins could modulate the phosphorylation of tau via the PI3K/Akt pathway. Specifically, we tested the well-established model in which the PI3K/Akt pathway is typically activated by extracellular signaling ligands (20). In this model, we hypothesized that select upstream cell surface signaling receptors are affected by presenilin activity rather than downstream signaling components.

The RTK family of cell surface receptors activates not only PI3K/Akt but also the MEK/ERK mitogen-activated protein kinase signaling pathway. This broad family includes the Trk neurotrophin receptors, fibroblast growth factor receptors, IGF-1 receptor, EGF receptor, and PDGF receptors, which are well known for their neurotrophic and/or neuroprotective properties (20, 21). Upon binding to their respective ligands, RTKs undergo dimerization and autophosphorylation of their cytoplasmic tails at multiple tyrosine residues. This leads to the recruitment and activation of a number of signaling molecules, including PI3K and Grb2/Sos. In one arm of RTK signaling, PI3K activates Akt, which then inactivates tau (22). In this study, we show that PS1 and PS2 differentially modulate GSK-3 activity via PI3K/Akt signaling induced by serum components and known ligands that activate their corresponding receptors.

**MATERIALS AND METHODS**

**Antibodies and Reagents**—The monoclonal antibody PSN2 (against residues 31–56 of human PS1) and polyclonal APP antibody CT15 (against C-terminal 15 residues of APP) have previously been described (23). Monoclonal antibodies against phosphotyrosine (Zymed Laboratories Inc.), phospho-ERK1/2 (Cell Signaling), and HFL2 (MBL) were obtained from commercial sources. Monoclonal antibodies against tau, PHF1 (Peter Davies), Tau-1 (Gloria Lee), and Tau46 (Gloria Lee) were generous gifts. Polyclonal antibody against phospho-202 tau was purchased from BIOSOURCE. Polyclonal antibodies against phospho-GSK3α/β, phospho-Akt, ERIK1/2, PDGFR3, IGf1-R, PS2 CTF, and phospho-33/37/41 β-catenin were purchased from Cell Signaling. Other reagents (PDGF-AA (Upstate Biotechnology, Inc.), PDGF-BB (Upstate Biotechnology), 125I-PGFBB-BB (Amersham Biosciences)), MEK inhibitor PD98059 (Calbiochem), PI3K inhibitor Wortmannin (Cell Signaling), proteasome inhibitor MG132 (Calbiochem), and polyclonal anti-PS1 N-terminal fragment (NTF) antibody (Calbiochem) were purchased from the indicated vendors.

cDNA Constructs—cDNAs encoding wild type PS1, wild type PS2, and PS2 M239V were subcloned into the retroviral vector pBabe-puro. cDNAs encoding PS2 D366A, PS2Δloop, wild type PS1, E280G, PS1 M146L, PS1 X9, PS1N-PS2C, and tau33 (gift from Gloria Lee) were also subcloned into pBabe-bio. The PS2Δloop construct contains an in-frame deletion of PS2 hydrophobic loop residues 309–352. The PS1N-PS2C construct fuses the NTF of PS1 (residues 1–280) with CTF of PS2 (residues 287–448), obtained from Dr. Gopal Thinakaran (24). All constructs were transfected together with a plasmid encoding the VSV-G envelope into 293GP packaging cells, and the resulting supernatants were prepared for retroviral transduction as previously described (25).

**Cell Lines and Transfections**—All cell lines were grown in DMEM containing 10% fetal bovine serum (FBS) unless explicitly stated otherwise. PS/−/+ and PS/−/− (genetically deficient in PS1 and PS2) have been described previously (16). To introduce PS1, PS2, or PS2MV into PS/−/− cells, corresponding retroviral supernatants from 293GP cells were added in the presence of 10 μg/ml polybrene and selected with 3 μg/ml puromycin. Resistant cells were pooled and maintained in the presence of 10 μg/ml polybrene without polybrene. PS1N-PS2C, PS2Δloop, PS1, PS1 E280G, PS1 M146L, PS1X9, PS1N-PS2C, or Tau33, corresponding retroviral supernatants were added to PS/−/−, PS/−/+ (hPS2), or PS/−/+ cells in the presence of 10 μg/ml polybrene and selected with 100 μg/ml bleocin. Resistant cells were pooled and maintained in the presence of appropriate antibiotic(s).

siRNA targeted for exon 3 of mouse FHL2 (sense, 5′-GGAGUGAGCUUAGGAAACU-3′) was purchased from Ambion. For RNA interference experiments, 25% confluent PS+/+ cells were transfected with a final concentration of 60 nm FHL2 siRNA twice using Lipofectamine 2000 (Invitrogen) over a 56-h period.

**Cell Lysing and Signaling Assays**—Cells were lysed in buffer containing 1% CHAPS, 0.5% SDS, 50 mM Tris (pH 8.0), 150 mM NaCl, 0.002% sodium azide, 400 mM Microcystin-LR, 0.5 μM sodium vanadate, and 1X Protease Inhibitor Cocktail (Roche Applied Science). Total RNA was isolated using the RNeasy mini kit from Qiagen. Two micrograms of total RNA were subjected to reverse transcriptase (RT) first strand synthesis using the Superscript kit (Invitrogen) according to the manufacturer’s instructions. Equal amounts of the RT product were placed on ice and washed four times with ice-cold phosphate-buffered saline. Cells were lysed in buffer containing 1% Triton X-100 buffer (identical to detection, cells were gently lysed in 1% Triton X-100 buffer (identical to CHAPS buffer with the exception of detergent) on ice for 10 min without scraping cells off of culture dishes. Triton X-100-insoluble materials (mostly nuclei) still remaining on culture plates were then solubilized with radiolabeled precipitation buffer (containing protease and phosphatase inhibitors) and sonicated to shear genomic DNA. For signaling assays, overnight confluent cultures were serum-starved in DMEM for 4 h, and ligands (PDGF-AA (25 ng/ml), PDGF-BB (25 ng/ml), EGF (25 ng/ml), and IGF-1 (50 ng/ml)) were added for the indicated times, or 20% FBS was added for 2 h. Protein quantitations from cell lysates were performed by the micro-BCA method (Pierce), and equal amounts of protein were then subjected to either direct immunoblotting with the appropriate antibodies or immunoprecipitation with a saturating amount of antibody and immunoblotted with phosphotyrosine antibody. All experiments were performed at least three times, and representative experiments and/or quantitations are shown.

**Reverse Transcriptase PCR Analysis—PS/+ +, PS/−/−, PS/−/+ (hPS1), and PS/−/− (hPS2) cells were grown to confluence, and total RNA was isolated using the RNeasy mini kit from Qiagen. Two micrograms of total RNA were subjected to reverse transcriptase (RT) first strand synthesis using the Superscript kit (Invitrogen) according to the manufacturer’s instructions. Equal amounts of the RT product were then used for PCR of PGDFRα or PGDFRγ within a linear range of amplification, empirically determined to be between 16 and 22 cycles. Quantitations were performed using a digital camera-based imaging system. All experiments were performed at least three times, and results were normalized to PS+/+ cells.

**Cell Surface 125I-PDGF-BB Binding Assays—** Overnight confluent cultures of PS/+ +, PS/−/−, PS/−/+ (hPS1), and PS/−/− (hPS2) were placed on ice and washed four times with ice-cold phosphate-buffered saline. 125I-PGF (0.625 μCi in 3% bovine serum albumin/phosphate-buffered saline) was added to cells in the presence or absence of a 100-fold excess of unlabeled PDGF-BB for 30 min. Unbound material was washed five times with 3% bovine serum albumin/phosphate-buffered saline on ice, cells were lysed in 0.2 N NaOH, and bound radioactivity was then quantitated by scintillation counting. Specific binding was calculated by subtracting the values from internal controls subjected to a 100-fold excess of unlabeled PDGF-BB. Experiments were conducted three times, and results normalized to PS+/+ cells are shown (means ± S.E.).
RESULTS

Loss of Presenilins Impairs PI3K/Akt and ERK Signaling, Elevates GSK-3 Activity, and Increases Tau Phosphorylation—We previously demonstrated that presenilin plays an important role in promoting the degradation of β-catenin, a key signaling intermediate in the Wnt signaling pathway, by acting as a scaffold upon which GSK-3-β-catenin, and a priming kinase are brought together to facilitate the stepwise phosphorylation of β-catenin (16). A primary mechanism of modulating GSK-3 activity is through its phosphorylation by the PI3K/Akt pathway, resulting in GSK-3 inactivation (26). Thus, we examined the phosphorylation status of GSK-3, indicative of general nonprimed GSK-3 activity, in PS−/− (lacking both PS1 and PS2) and PS+/+ control fibroblasts. Under basal cell culture conditions with 10% FBS, the phosphorylation of both GSK-3α (upper band) and GSK-3β (lower band), representing the inactive kinase, was substantially reduced in PS−/− fibroblasts (Fig. 1A). Because GSK-3 is a major tau kinase, we next expressed human four-repeat tau in PS+/+ and PS−/− fibroblasts to assess whether tau phosphorylation is differentially affected by this alteration in GSK phosphorylation. Indeed, phosphorylated tau on residues 202 and 396/404 (PHF1), two GSK-3 sites, was substantially elevated in PS−/− cells under basal conditions (Fig. 1A), consistent with recent observations in PS1-deficient cells and in forebrains of mice lacking both PS1 and PS2 (9, 10). Since GSK-3 can be inactivated by PI3K/Akt-mediated phosphorylation (26), we assessed the phosphorylation status of Akt in PS+/+ and PS−/− cells. As expected, the active phosphorylated species of Akt (P-Akt) was substantially reduced in presenilin-deficient cells (Fig. 1B) under basal conditions, consistent with the reduced phosphorylation of GSK-3 species. Further, because PI3K/Akt activation is principally generated by cell surface RTKs that also signal through the MEK/ERK mitogen-activated protein kinase pathway, we next examined whether the activation of ERK is affected by the loss of presenilins. Indeed, the active phosphorylated ERK1 and -2 (P-ERK1/2) species were also substantially reduced in PS−/− cells under basal conditions (Fig. 1B), indicating that the perturbations in ERK and Akt phosphorylation may both be regulated by upstream RTK activity.

Severe Impairment in Akt and ERK Activation via Select Receptor Tyrosine Kinases in Presenilin-deficient Cells and Effects on Tau Phosphorylation—The novel observation that both Akt and ERK signaling pathways were impaired by presenilin deficiency led us to hypothesize that select cell surface receptors themselves rather than downstream signaling factors are primarily affected by presenilins. Thus, as a first step, we examined the signaling events activated by several prototypic growth factors (PDGF-BB, PDGF-AA, IGF-1, and EGF). The addition of IGF-1 or EGF to serum-starved PS+/+ or PS−/− cells for varying time intervals demonstrated robust Akt and ERK phosphorylation in both genotypes, which did not markedly differ from each other (supplemental Fig. 1A). In contrast, PDGF-BB (25 ng/ml) or PDGF-AA (25 ng/ml) induced activation of PI3K/Akt/GSK-3 and ERK1/2 phosphorylation after serum deprivation was severely reduced in PS−/− cells (Fig. 1C, supplemental Fig. 1B). In the same experiments, activation of Akt by PDGF had no effect on the GSK-3-mediated phosphorylation of β-catenin (33/37/41) in either PS+/+ or PS−/− cells (Fig. 1C), indicating that GSK-3 activity on β-catenin through priming and scaffolding mechanisms is independent of Akt-mediated control of GSK-3 activity. In dose-response experiments, we found that the response to PDGF-BB was saturated at 25 ng/ml and did not increase further at 50 ng/ml in both PS+/+ and PS−/− cells, although the magnitude of the response was much weaker in PS−/− at all concentrations tested (supplemental Fig. 1C). This suggested abnormalities in receptor activity and/or expression in PS−/− cells. Indeed, the level of PDGFrβ protein, especially the mature glycosylated product, was reduced by ~3-fold in PS−/− cells (Fig. 2A). Quantitative RT-PCR analysis also consistently showed that both PDGFrβ and PDGFrα mRNAs were reduced by more than 2-fold in PS−/− cells (Fig. 2B and C), closely mirroring the protein levels. Moreover, the number of specific 125I-PDGF-BB binding sites on the cell surface of PS−/− cells was similarly reduced by >2-fold (Fig. 2D). Finally, there was also a strong decrease in PDGF-induced activation and autophosphorylation of PDGFrβ in PS−/− cells (Fig. 2A), the magnitude of which closely reflected the level of Akt and ERK phosphorylation (Fig. 1C). Upon ligand exposure and autophosphorylation, PDGFR is normally rapidly internalized and degraded in lysosomes (27). In serum-starved PS+/+ cells,
PDGF reliably induced the rapid loss of PDGFR (supplemental Fig. 2A). In contrast, ligand-induced degradation of PDGFR was completely absent in PS−/− cells up to 1 h, consistent with the considerable reduction in PDGFR activation and autophosphorylation from the cell surface (supplemental Fig. 2A).

Since GSK-3 inactivation was markedly reduced upon PDGF signaling in presenilin-deficient cells, we reexamined PS+/+ and PS−/− cells stably transfected with four-repeat tau for potential PDGFR-induced changes in tau phosphorylation. Treatment of PDGF-BB suppressed the phosphorylation of tau in serum-deprived PS+/+ but not PS−/− cells, as evidenced by two well characterized antibodies, the dephospho-tau antibody Tau-1 (dephospho-202/205, lower band) and phospho-tau antibody PHF1 (phospho-396/404) (Fig. 3). The magnitude of reduction in PHF1 and increase in Tau-1 immunoreactivity upon PDGF treatment in PS+/+ cells was ~40 and ~250%, respectively. This reduction in tau phosphorylation was blocked by the specific PI3K inhibitor wortmannin but not the mitogen-activated protein kinase/MEK1 inhibitor PD98059 (Fig. 3), indicating that the PI3K/Akt/GSK-3 pathway plays the major role in this reduction of tau phosphorylation.

**Differential Effects of PS1 and PS2 in Akt/ERK Activation via PDGFR**—Because the alterations in Akt and ERK activation were seen in fibroblasts deficient in both PS1 and PS2 (PS−/−), it is unclear whether the defects are secondary to PS1, PS2, or both species. Therefore, wild type human PS1 or PS2 was expressed in PS−/− cells to assess whether either or both presenilins can rescue this phenotype. Similar with results from a previous study (17), we found that reconstitution of PS1 expression in PS−/− cells facilitated PI3K/Akt signaling induced by FBS after serum deprivation compared with parental PS−/− cells (Fig. 4A and supplemental Fig. 3A). However, this activity was not confined to PS1, as PS2 also similarly increased Akt activation (Fig. 4A and supplemental Fig. 3A). In addition, both PS1 and PS2 increased FBS-induced ERK1/2 activation, with PS2 showing an overall stronger degree of rescue (Fig. 4A and supplemental Fig. 3A). Surprisingly, Akt and ERK signaling induced by treatment of PDGF-BB or PDGF-AA was restored by PS2 but not by PS1 (Fig. 4, B and C). This rescue of phenotype by PS2 was accompanied by increased PDGFR expression, maturation (upper band, mature; lower band, immature), and PDGF-induced receptor tyrosine phosphorylation, in contrast to that seen with PS1 (Fig. 4A). Moreover, quantitative RT-PCR analysis also showed that PS−/− cells transfected with PS2 selectively restored the levels of both PDGFRα and PDGFRβ mRNA to levels comparable with those in PS+/+ cells (see Fig. 6, D and E). Similarly, PS2 preferentially reconstituted cell surface 125I-PDGF-BB binding to levels seen in PS+/+ cells (Fig. 4F). Unlike its wild type counterpart, the PS2 M239V FAD mutation exhibited little to no activity in restoring PDGF-AA- or PDGF-BB-induced Akt and ERK activation or PDGFR expression (Figs. 4C and 6A and supplemental Fig. 3), although the level of PS2 CTF was identical to wild type PS2 (Fig. 4C). Taken together, these results demonstrate that whereas both PS2 and PS1 can facilitate Akt and ERK activation induced by serum components,
wild type PS2 but not PS2 M239V mutation or PS1 facilitates PDGF-mediated signaling by regulating the expression of PDGF receptors.

**Role of PS2 N-terminal Fragment but Not γ-Secretase Activity or Large Hydrophilic Loop of PS2 in PDGF-induced Akt/ERK Activation**—Since the major function of the presenilin complex is to mediate the proteolysis of intramembrane peptide bonds as an intramembrane cleaving protease (I-CLIP), we next asked whether the γ-secretase activity of PS2 might be involved in PDGF-induced Akt/ERK activation. We initially utilized pharmacological γ-secretase inhibition with the compound L685,458 for varying time intervals in PS+/+ cells. Serum-starved PS+/+ cells were pretreated with L685,458 for 4 h before and during the addition of PDGF-BB for 0, 15, 30, and 60 min. Under these conditions, pharmacological γ-secretase inhibition had no effect on PDGFIR levels, ligand-induced degradation of PDGFIR, or Akt phosphorylation but, as expected, elevated APP C-terminal fragment (CTF) levels (supplemental Fig. 2B). This indicated that active γ-secretase inhibition does not interfere with the rapid ligand binding and intracellular PDGF-induced signaling events. We next tested whether potential changes due to prolonged or chronic γ-secretase inhibition could affect PDGF signaling. For these experiments, PS+/+ cells were treated with L685,458 for 48 h before and during serum withdrawal and the addition of PDGF. In contrast to the short term treatment, prolonged treatment with γ-secretase inhibitor resulted in marked reduction in PDGFR levels and corresponding diminution in PDGF-induced Akt/ERK activation (supplemental Fig. 2C). This suggested that indirect changes resulting from prolonged catalytic γ-secretase inhibition and/or the physical binding of the inhibitor to presenilins underlie this effect.

To determine the direct role of PS2 catalytic γ-secretase activity, we tested whether the critical aspartate on position 366 of PS2, required for γ-secretase activity (28), is also required for PDGF-induced Akt/ERK activation (Fig. 5A). As expected in PS−/− cells stably transfected with the PS2 D366A mutation, no endoproteolytic fragment of PS2 was detected, and the full-length PS2 D366A was expressed at levels similar to wild type PS2 CTF (Fig. 5B). Under these conditions, treatment of PDGF-BB to PS−/− (hPS2 D366A) cells after serum deprivation consistently resulted in restoration of Akt/ERK activation comparable with wild type PS2, conclusively demonstrating that the proteolytic γ-secretase activity of PS2 is dispensable for this effect. Thus, the reduction in PDGFIR expression secondary to prolonged exposure to γ-secretase inhibitor is not attributable to the inhibition of catalytic γ-secretase activity per se but is probably due to functional changes in conformation of the PS2 protein while bound to the γ-secretase inhibitor.

Since PS2 but not PS1 was capable of facilitating PDGF signaling, we next set out to outline the region of PS2 involved in this activity. Two major regions in PS2 are highly divergent in sequence from PS1: the large hydrophilic loop and NTF excluding transmembrane domains. However, it is also notable that a single FAD PS2 M239V mutation is sufficient to abrogate activity with regard to PDGF signaling (Figs. 4C and 6A and supplemental Fig. 3B), indicating high sensitivity to changes in protein structure caused by select mutations. The hydrophilic loop regions of PS1 and PS2 are devoid of FAD mutations and appear not to change the conformation/structure of presenilin proteins. For example, the large hydrophilic loops of PS1 or PS2 are not required for γ-secretase activity and are neutral to changes in Ap42 caused by PS FAD mutations (29). Thus, a PS2Δloop construct lacking residues 309–352 of PS2 (divergent sequences in the PS2 loop) was stably expressed in PS−/− cells. Immunoblot analysis showed that the PS2 NTF of PS2Δloop was expressed at levels similar to that of the wild type PS2 counterpart (Fig. 5C). Likewise, serum starvation and the addition of PDGF-BB demonstrated that the PS2Δloop restores Akt/ERK activation to levels comparable with wild type PS2 (Fig. 5C). Thus, the divergent sequences 309–352 in the large hydrophilic loop of PS2 are not required for this activity. To assess the contribution of PS2 NTF in PDGF signaling, we next expressed a fusion chimeric protein (PS1N-PS2C) in which PS1 NTF (residues 1–280) was fused to PS2 C-terminal fragment (PHF1). Note the reduction of tau phosphorylation by PDGF-BB in PS+/+ but not PS−/− cells as well as the complete reversal of tau dephosphorylation in PS+/+ cells by Wortmannin but not PDGF8059. A representative experiment is shown. B and C, graphs show quantitations from three experiments representing the relative levels of Tau-1 (dephospho-202/205) and PHF1 (phospho-396/404) reactivity from PS+/+ cells normalized to no-treatment control. The error bars represent S.E.
required for PDGF-induced activation of Akt/ERK and cannot be substituted by PS1.

Role of FHL2 in PS2-mediated Control of PDGFR Expression—Three proteins are known to selectively interact with PS2 but not PS1: calmyrin, sorcin, and FHL2 (30–32). Among these, FHL2 (also called DRAL) is a LIM domain protein that interacts with PS2 NTF and functions as a transcriptional co-activator for a number of different transcriptional complexes (33–35). Because PDGFR mRNA and protein levels were significantly reduced in PS−/− cells and restored by PS2, we hypothesized that PS2 might alter the biology of FHL2 and, in turn, affect PDGFR levels. FHL2 is a soluble protein that normally shuttles between the cytoplasm and the nucleus. To test whether FHL2 levels and/or localization are altered by PS2 variants or PS1, we separated Triton X-100-soluble and -insoluble materials from PS+/*, PS−/*, PS−/* (hPS2), PS−/* (hPS1), and PS−/* (hPS2 M239V), and PS−/* (hPS1) cells on culture dishes without using a cell scraper. Microscopic examination of the insoluble material remaining on culture dishes after Triton extraction revealed a nearly complete absence of membranes/cytosol and the salient presence of almost exclusively nuclei and few cytoskeletal elements. The Triton X-100-insoluble material was then solubilized in radiolmmune precipitation buffer with sonication to shear the genomic DNA. By immunoblotting, the levels of Triton X-100-insoluble and presumably nuclear FHL2 protein were significantly diminished in PS−/* cells compared with PS+/* cells and restored by wild type PS2 but not PS2 M239V or PS1 (Fig. 6A). This tightly correlated with PDGFR levels in these cells (i.e. the capacity to signal via PDGFR) (Fig. 6A), suggesting that PS2 might regulate PDGFR levels through FHL2. A similar but much weaker correlation between FHL2 and PDGFR level was seen in the Triton X-100-
the N-terminal fragment but not the catalytic (residues 1–280) with PS2 CTF (residues 287–448). The hydrophilic loop of PS2, whereas PS1N-PS2C represents a fusion of PS1 NTF and the arrow constructs. The expression of PDGFR in confluent cultures of parental PS2 is required for PDGF-induced Akt and ERK activation. Overnight starvation and stimulation with PDGF-BB, we also observed a modest reduction in Akt activation upon FHL2 siRNA transfection, presumably resulting from the decrease in PDGFR expression (Fig. 6B, lower panel). Thus, FHL2 positively regulates PDGFR expression directly or indirectly. This at least partially explains the decrease in PDGFR in PS−/− cells. Because PS2 restored nuclear FHL2 levels in PS−/− cells and knockdown of FHL2 reduced PDGFR expression in PS+/+ cells, we interpret these data to indicate that PS2 facilitates PDGFR signaling through an FHL2-mediated increase in PDGFR expression.

**PS1 Mutations Inhibit Serum- and PDGF-induced Akt/ERK Activation**—The inability of PS1 to restore PDGFR-induced Akt/ERK activation in PS−/− cells can be explained by the failure to restore FHL2 and PDGFR levels. However, we found that PS1 could facilitate Akt activation induced by FBS (Fig. 4A). This observation is analogous to a previous study in which PS1 enhanced Akt phosphorylation in E-cadherin-transfected PS1−/− cells in FBS-containing culture conditions (17). Thus, the mechanisms by which presenilins augment Akt/ERK signaling via PDGF and serum are at least partially distinct. In previous studies, it was also reported that FAD PS1 mutations suppress the basal level of PI3K/Akt activation compared with wild type PS1 in cells where PS2 was not experimentally altered (17, 19). To investigate whether similar results could be observed in our experimental setting, wild type PS1 or two PS1 FAD mutations (E280G and M146L) were stably expressed in PS−/− cells previously transfected with human PS2 (PS−/− (hPS2)). Immunoblot analysis showed that PS1 NTF expression was comparable between wild type and mutant proteins, with little to no detectable full-length PS1 (Fig. 7A). Upon serum withdrawal and treatment with 20% FBS for 2 h, we found that FAD mutations noticeably suppressed Akt activation compared with wild type PS1 (Fig. 7A), results that are similar to those seen in previous studies in different cellular models (17, 19). In addition, serum-induced ERK1/2 phosphorylation was also reduced by FAD mutations compared with wild type PS1 (Fig. 7A), suggesting that both Akt and ERK pathways are altered by PS1 via a common mechanism. Surprisingly, although the level of PS1 expression was comparable among wild type and mutant PS1 proteins, there was >2-fold reduction of PS2 CTFs in cells expressing FAD PS1 mutations compared with wild type PS1 (Fig. 7A). Accordingly, serum withdrawal and PDGF-AA treatment showed that FAD mutations also reduced PDGF-dependent Akt/ERK activation compared with wild type PS1 (Fig. 7B–D). Specifically, whereas both mutations inhibited Akt and ERK phosphorylation, the PS1 E280G mutation showed a stronger effect, with an average reduction in PDGF-induced Akt and ERK phosphorylation by 62 and 70%, respectively (Fig. 7, B–D). Similar results were seen after serum withdrawal and treatment with PDGF-BB (not shown). These results taken together indicate that FAD PS1 mutations suppress not only Akt and ERK activation induced by serum components but also that induced by PDGF, the latter of which is dependent on PS2 levels. Moreover, these data raise the intriguing possibility that multiple PS1 activities may in part function in coordination with PS2.

**FIG. 5.** A, schematic of wild type PS2 and different PS2 mutant constructs. The open boxes represent the transmembrane domains 1–8, and the asterisks indicate positions of D366A and M239V PS2 mutations. The arrow indicates the position of endoproteolytic cleavage. PS2loop represents a deletion of residues 309–352 within the hydrophilic loop region of PS2, whereas PS1N-PS2C represents a fusion of PS1 NTF and the arrow constructs. The expression of PDGFR in confluent cultures of parental PS2 is required for PDGF-induced Akt and ERK activation. Overnight starvation and stimulation with PDGF-BB, we also observed a modest reduction in Akt activation upon FHL2 siRNA transfection, presumably resulting from the decrease in PDGFR expression (Fig. 6B, lower panel). Thus, FHL2 positively regulates PDGFR expression directly or indirectly. This at least partially explains the decrease in PDGFR in PS−/− cells. Because PS2 restored nuclear FHL2 levels in PS−/− cells and knockdown of FHL2 reduced PDGFR expression in PS+/+ cells, we interpret these data to indicate that PS2 facilitates PDGFR signaling through an FHL2-mediated increase in PDGFR expression.

**PS1 Mutations Inhibit Serum- and PDGF-induced Akt/ERK Activation**—The inability of PS1 to restore PDGFR-induced Akt/ERK activation in PS−/− cells can be explained by the failure to restore FHL2 and PDGFR levels. However, we found that PS1 could facilitate Akt activation induced by FBS (Fig. 4A). This observation is analogous to a previous study in which PS1 enhanced Akt phosphorylation in E-cadherin-transfected PS1−/− cells in FBS-containing culture conditions (17). Thus, the mechanisms by which presenilins augment Akt/ERK signaling via PDGF and serum are at least partially distinct. In previous studies, it was also reported that FAD PS1 mutations suppress the basal level of PI3K/Akt activation compared with wild type PS1 in cells where PS2 was not experimentally altered (17, 19). To investigate whether similar results could be observed in our experimental setting, wild type PS1 or two PS1 FAD mutations (E280G and M146L) were stably expressed in PS−/− cells previously transfected with human PS2 (PS−/− (hPS2)). Immunoblot analysis showed that PS1 NTF expression was comparable between wild type and mutant proteins, with little to no detectable full-length PS1 (Fig. 7A). Upon serum withdrawal and treatment with 20% FBS for 2 h, we found that FAD mutations noticeably suppressed Akt activation compared with wild type PS1 (Fig. 7A), results that are similar to those seen in previous studies in different cellular models (17, 19). In addition, serum-induced ERK1/2 phosphorylation was also reduced by FAD mutations compared with wild type PS1 (Fig. 7A), suggesting that both Akt and ERK pathways are altered by PS1 via a common mechanism. Surprisingly, although the level of PS1 expression was comparable among wild type and mutant PS1 proteins, there was >2-fold reduction of PS2 CTFs in cells expressing FAD PS1 mutations compared with wild type PS1 (Fig. 7A). Accordingly, serum withdrawal and PDGF-AA treatment showed that FAD mutations also reduced PDGF-dependent Akt/ERK activation compared with wild type PS1 (Fig. 7B–D). Specifically, whereas both mutations inhibited Akt and ERK phosphorylation, the PS1 E280G mutation showed a stronger effect, with an average reduction in PDGF-induced Akt and ERK phosphorylation by 62 and 70%, respectively (Fig. 7, B–D). Similar results were seen after serum withdrawal and treatment with PDGF-BB (not shown). These results taken together indicate that FAD PS1 mutations suppress not only Akt and ERK activation induced by serum components but also that induced by PDGF, the latter of which is dependent on PS2 levels. Moreover, these data raise the intriguing possibility that multiple PS1 activities may in part function in coordination with PS2.
FIG. 6. A, nuclear FHL2 levels correlate with PDGFR expression and the capacity to signal via PDGF. Overnight confluent cultures of PS+/+,
PS−/−, PS−/− (hPS2), PS−/− (hPS2 M239V), and PS−/− (hPS1) cells were solubilized with 1% Triton X-100 buffer on ice. The Triton
X-100-insoluble nuclei remaining on culture dishes were then solubilized with radioimmune precipitation buffer and subjected to sonication. In the
upper panel, equal protein amounts of Triton X-100-insoluble nuclear fraction were immunoblotted for FHL2. In the lower two panels, equal protein
amounts of Triton X-100-soluble material were immunoblotted for PDGFRβ and total Akt. B, experimental reduction in FHL2 results in lower
PDGFRβ levels in PS−/− cells. Twenty-five percent confluent PS−/− cells were transfected with Lipofectamine 2000 plus FHL2 siRNA or
Lipofectamine alone for 56 h. In the upper three panels, cells were lysed in 1% Triton X-100 buffer, and equal protein amounts were subjected to
immunoblotting for FHL2, PDGFRβ, and total Akt. In the bottom panel, cells were serum-starved for 4 h and treated with PDGF-BB (25 ng/ml)
for 30 min, and equal protein amounts were immunoblotted for phospho-Akt. A representative experiment is shown. C, the graph represents the
average level of FHL2 and PDGFRβ protein in PS+/+ cells after FHL2 siRNA transfection normalized to mock transfection from three experiments. The error bars represent S.E.

FIG. 7. A, FAD PS1 mutations inhibit serum-induced Akt and ERK activation and lower PS2 fragment levels. Confluent cultures of PS−/− (hPS2) cells stably transduced with wild type PS1, PS1 E280G, or PS1 M146L were serum-starved for 4 h in DMEM and treated with FBS to a final concentration of 20% for
2 h. Cell lysates were then subjected to immunoblotting for phospho-ERK1/2, phospho-Akt, total Akt, PS1 NTF, and PS2 CTF. A representative experiment is shown. B–D, PS1 FAD mutations suppress PDGF-induced Akt and ERK activation. Confluent cultures of PS−/−
(hPS2) cells stably transduced with wild type PS1, PS1 E280G, or PS1 M146L were serum-starved for 4 h in DMEM and treated with PDGF-AA for the indicated times or FBS (20% final) for 2 h. Cell lysates were then subjected to immunoblotting for phospho-Akt, total Akt, and phospho-ERK1/2. A representative experiment is shown in B. The graphs in C and D show quantitations from three experiments representing the levels of phospho-Akt and phospho-ERK after 5 min of PDGF-AA treatment normalized to wild type PS1 controls. The error bars represent S.E.
DISCUSSION

Presenilins in Akt/ERK Signaling and Tau Phosphorylation via Select Cell Surface Signaling Receptors—Accumulating evidence suggests that presenilins play important roles in Akt/GSK signaling and tau phosphorylation that may impinge on the pathology of neurodegenerative diseases. It has been reported that FAD PS1 mutations reduce Akt activity, increase GSK-3 activity, and render PC12 cells more vulnerable to apoptosis (19). Moreover, the loss of PS1 and FAD PS1 mutations were reported to enhance tau phosphorylation and reduce kinesin-based transport by increasing GSK-3 activity in primary neurons (18). These earlier studies, however, did not provide a mechanistic framework by which PS1 or FAD mutations could potentially account for these effects. In a recent study using E-cadherin-transfected PS1-deficient and control cells, it was proposed that one mechanism by which PS1 could activate Akt and reduce tau phosphorylation is by bridging the p85 regulatory subunit of PI3K to cadherins, the loss of which abrogated cadherin-mediated activation of Akt in PS1-deficient cells (17). In this cadherin-dependent model, wild type PS1 facilitates the recruitment and activation of PI3K on cadherins upon cell-cell interactions, whereas FAD PS1 mutations inhibit this process.

In this study, we used PS1/PS2 double deficient cells (PS−/−) without E-cadherin overexpression. Thus, our results are contextually distinct from the study by Baki et al. (17) and need to be interpreted accordingly. However, it is clear from this study that the cadherin-based mechanism of Akt activation is but one of multiple routes by which presenilins facilitate signaling from the cell surface. Indeed, the loss of presenilins markedly diminished not only Akt but also ERK activation induced by PDGF-AA, PDGF-BB, or FBS. The last ERK pathway is not known to be activated by cadherins. In contrast, signals activated by EGF or IGF-1 were comparatively intact in terms of the loss of presenilins, indicating that the capacity to signal through Akt/ERK is essentially intact in PS−/− cells. These data taken together indicated that deficits in Akt/ERK activation originated from select cell surface signaling receptors rather than downstream signal transduction mechanisms. Indeed, the specific defects in PDG signaling in PS−/− cells were due to a marked reduction in the expression and activation of PDGF receptors. Based on the current and previous studies, signaling receptors affected by presenilins now include TrkB (13), cadherins (17), PDGFRα, and PDGFRβ.

Selectivity of PS2 in PDGF-induced Signaling Independent of γ-Secretase Activity—The observation that PS1 restored Akt signaling induced by FBS in PS1/PS2 double deficient cells is analogous with previous results in E-cadherin-transfected PS1 single deficient cells in which PS1 restored Akt activation (17). However, this was not unique to PS1, since we found that PS2 also rescued this phenotype. Thus, the degree of rescue by PS1 and PS2 is probably additive and dependent on the overall expression of both presenilins. This may explain the observed deficit in Akt activation by the loss of PS1 alone in the previous study. Moreover, it is notable that E-cadherin binds to PS1 through a region that is not conserved in PS2 (36); thus, E-cadherin overexpression in the previous study (17) probably amplified the PS1-dependent cadherin-based route of Akt activation. The manner in which presenilins facilitated FBS-induced Akt and ERK activation in the current study is unknown. In addition to the deficits in cadherin-mediated Akt activation, we hypothesize that other signaling receptors activated by serum components are also compromised by loss of presenilins. Such receptors probably resemble receptor tyrosine kinases, since both Akt and ERK pathways are concomitantly affected.

Unlike signaling induced by FBS, Akt/ERK activation induced by PDGF treatment was selectively reconstituted by PS2 but not PS1, indicating at least partially distinct mechanisms. The NTF of PS2 (residues 1–286) was required for restoring PDGF signaling in PS−/− cells and could not be substituted by the same region in PS1. It has been documented that the highly divergent hydrophilic loops of PS1 and PS2 are neither required for γ-secretase activity nor sensitive to changes in Aβ42 caused by FAD mutations (29). Likewise, the large hydrophilic loop (residues 309–352) of PS2 was dispensable for PDGF-induced Akt/ERK phosphorylation. Furthermore, the catalytic γ-secretase activity of PS2 was completely dispensable for this activity, since PS2 D366A, a catalytic γ-secretase-defective mutant, was fully capable of restoring PDGF-induced Akt/ERK activation. This biological property of PS2 therefore adds to a growing list of presenilin-mediated functions that are not dependent on catalytic γ-secretase activity (12, 14, 16).

Despite the functional rescue of PDGF signaling by the catalytically dead PS2 D366A mutation, prolonged treatment of γ-secretase inhibitor in PS+/+ cells reduced PDGFR levels and signaling, at least partially mimicking the PS−/− state. This apparent discrepancy therefore emphasizes caution in the interpretation of results secondary to the use of pharmacologic γ-secretase inhibitors. For example, γ-secretase inhibitors not only inhibit the catalytic protease activity of the γ-secretase complex but also alter the trafficking of presenilin fragments and Pen-2 (37). Thus, the binding of γ-secretase inhibitors to the presenilin complex can alter the biology of presenilins that are dependent and independent of γ-secretase activity, a latter phenotype seen by the reduction in PDGFR expression and PDGF signaling. In dose response experiments, certain γ-secretase inhibitors, such as L685,458, elevate the Aβ42/Aβ40 ratio at low concentrations prior to complete inhibition of γ-secretase activity at higher concentrations (38). Thus, γ-secretase inhibitors may also functionally alter the conformation of PS2 to resemble a mutant state, much like the PS2 M239V mutation that failed to restore PDGF signaling and PDGFR expression in PS−/− cells.

FHL2 in PS2-mediated PDGFR Expression—The observation that PDGF receptors were reduced at the level of protein and mRNA by the loss of presenilins and selectively rescued by PS2 but not PS1 suggested indirect transcriptional control of PDGFR by PS2. Among three proteins that are known to interact specifically with PS2 but not PS1, we first selected FHL2 for further study, because it binds to the NTF of PS2 and fulfills the criteria as a potential transcriptional candidate. The direct physical association between FHL2 (also called DRAL) and PS2 was previously discovered in a yeast two-hybrid screen and confirmed in co-immunoprecipitation experiments (32). FHL2 was first identified as a co-activator of the androgen receptor (39) and was later found to function as either a co-activator or co-repressor of multiple transcriptional assemblies. For example, FHL2 co-activates AP-1 (35), CREB/cAMP-response element modulator (33), and CBP/β-catenin (34), whereas it co-represses FOXO1 (40). Our initial observation that Triton X-100-insoluble nuclear FHL2 levels were significantly diminished in PS−/− cells and restored by PS2 but not PS1 suggested a positive role of FHL2 in PS2-mediated PDGFR expression and signaling. Fulfilling this prediction, experimental reduction of FHL2 in PS+/+ cells by RNAi indeed led to a significant decrease in PDGFR, indicating that PDGFR is either a direct or indirect target of FHL2-mediated transcriptional co-activation. Thus, we interpret these results to indicate that PS2 facilitates PDGFR expression, at least in part, through FHL2-mediated co-activation of PDGFR.

The manner by which FHL2 co-activates PDGFR expression
or PS2 enhances nuclear FHL2 levels is unknown. One potential mechanism by which PS2 can increase nuclear FHL2 levels is by facilitating its nuclear translocation. FHL2 normally translocates into the nucleus in the presence of serum (35). Given that a major fraction of PS2 is found in membranes of the outer nuclear envelope and endoplasmic reticulum, the juxtaposition of PS2 to the nucleus may serve to facilitate the normal serum-induced route of FHL2 nuclear translocation. In the nucleus, FHL2 directly interacts with CBP/p300 and synergistically co-activates target genes (34). Since CBP/p300 facilitates NF-Y-induced stimulation of the PDGFRβ promoter (41), it is conceivable that FHL2 synergistically enhances this transcriptional route of PDGFR expression.

The M239V mutation, unlike its wild type counterpart, failed to rescue PDGFR expression and signaling when expressed in PS−/− cells. Likewise, it also failed to restore nuclear FHL2 levels, consistent with the involvement of FHL2 in PDGFR expression. However, the PS2 M239V mutation is not contained within a putative FHL2 binding site (residues 269–298 of PS2) (32). We interpret this to suggest that conformational changes caused by this mutation also abrogate functional interactions with FHL2. The PS1N-PS2C protein, which failed to reconstitute PDGF signaling in PS−/− cells, lacks the entire NTF of PS2, including the putative FHL2 binding site, consistent with the role of FHL2 in PS2-mediated PDGFR signaling.

The possibility that additional mechanisms unrelated to FHL2 might be involved in PS2-mediated PDGFR signaling cannot be fully precluded by this study. Presenilins are known to mediate the trafficking and maturation of select membrane proteins and/or intracellular vesicles. For example, glycosylation, trafficking, and signaling of TrkB are altered in PS1-deficient neurons (13), and α-synuclein and telencephalin accumulate in large vacuolar structures resembling autophagosomes by PS1 deficiency (12, 14). Thus, it is conceivable that PS2 is also involved in mediating the proper trafficking of vesicles containing PDGFRs in addition to its effects on PDGFR expression. The observation that PDGF-induced degradation of PDGFR was absent in PS−/− cells may be evidence of such a trafficking defect.

**FAD PS1 Mutations in Serum and PS2-mediated PDGFR Signaling**—Previous studies have reported that FAD PS1 mutations suppress the basal level of Akt activation in two different cell culture models in which PS2 was not experimentally altered (17, 19). Indeed, the current results confirmed this prediction in our own cell culture system using PS−/− cells stably transfected with PS2. One surprising finding was that PS1 FAD mutations led to a substantial reduction in PS2 fragment levels compared with wild type PS2. This in turn resulted in a corresponding decrease in PDGFR-induced Akt and ERK activation by FAD PS1 mutations (E280G and M146L) compared with wild type PS1. The generation of PS1 and PS2 fragments are coordinately controlled by competition for limiting cellular factors. Therefore, extreme overexpression of either PS1 or PS2 can cross-interfere with the generation of both PS1 and PS2 fragments (28, 42). However, the expressions of wild type and mutant PS1 proteins in this study were similar, with little to no detectable full-length molecule. Therefore, it is unlikely that the reduction in PS2 CTF by PS1 mutations is due to differences in the expression of PS1 variants. Instead, it has been demonstrated that whereas both wild type and FAD mutant PS1 fragment levels reach a saturation point regardless of excess full-length precursor, fragments derived from FAD PS1 mutations (A246E and M146L) tend to accumulate more readily than those of wild type PS1 prior to the saturation point (43). Therefore, the reduction of PS2 CTF by FAD PS1 mutations compared with wild type PS1 may reflect the tendency of FAD mutants to more effectively compete for limiting cellular factors needed for generating PS1 fragments at the expense of PS2. In this way, FAD PS1 mutations would not only impinge on PS1 but also on PS2 activities, as observed with PDGF signaling in this study. These results taken together demonstrate that the coordinated actions of both PS1 and PS2 are important in Akt and ERK signaling via selective cell surface signaling receptors and suggest the possibility that FAD presenilin mutations might compromise neuroprotective Akt and ERK signaling through both PS1- and PS2-dependent pathways in brain.

**In Vivo Correlations to Neurodegeneration Associated with Loss of Presenilins**—A recent study documented that the G183V PS1 mutation co-segregates with pathologically confirmed familial frontotemporal dementia (6), a tauopathy lacking Aβ/amyloid. This finding, together with two recent studies showing striking neurodegeneration, hyperphosphorylation of tau, and memory deficits by the conditional loss of both PS1 and PS2, strongly indicates that perturbations in presenilin functions can directly impinge on tangle pathology and neurodegeneration (9, 10). However, the mechanisms by which the loss of presenilin results in these phenotypes are unknown. We hypothesize that defects in Akt and ERK activation by loss of presenilins seen in this study, at least in part, account for such a neurodegenerative phenotype seen in the PS dKO mice. **FIG. 8. Proposed model of presenilins in neurodegeneration and tau phosphorylation via cell surface signaling receptors.** This model proposes that presenilins normally function to promote Akt and/or ERK signaling via PDGFRs, TrkB (13), cadherins (17), and as yet unidentified signaling receptors. However, such signaling functions are compromised by mutations or dysfunctions in either PS1 or PS2. Mutations in PS1 may also lead to interference of PS2 function and vice versa, such as the inhibition of PS2-mediated PDGFR signaling by FAD PS1 mutations. Through select signaling receptors, activated PI3K/Akt inhibits multiple proapoptotic pathways (**i.e.** BAD and FOXO), activates pro-survival NF-κB, and inhibits GSK-3, all leading to enhanced neuronal survival and reduced tau phosphorylation. Simultaneously, the activation of the MEK/ERK pathway stimulates protein synthesis, changes ion channel properties, and stimulates CREB-mediated transcription, pathways important for gene expression and consolidation of memory. Thus, deficits in Akt and ERK activation by presenilin dysfunctions are predicted to increase the phosphorylation of tau, render neurons more vulnerable to degeneration, and impair learning and memory.
PS2 in PDGF Signaling

PI3K/Akt signaling is known to inactivate the tau kinase GSK-3, inhibit several proapoptotic pathways, and activate the PI3K/Akt signaling is known to inactivate the tau kinase PS2C construct, Dr. Bart De Strooper for the PS2 and antibodies (Tau-1 and Tau46), Dr. Peter Davies for the PHF1/PS likely that these receptors alone can account for the degeneration is also inhibited by dysfunctions in APP and apoE receptors ferring of N-cadherin to the cell surface (48). Although the precise mechanisms underlying the perturbations in each of these signaling receptors appear to be distinct, they all signal through the common PI3K/Akt and/or MEK/ERK pathways. Based on the current data and previous studies, we propose a model in which mutations or dysfunctions in PS1 or PS2 partially interfere with select cell surface signaling receptors and that such inhibition may constitute a pathogenic mechanism for accelerated neurodegeneration and tau pathology (Fig. 8). The accumulation of the pathogenic Aβ42 species probably further compromises this neuroprotective process. Recent studies have also documented that the PI3K/Akt signaling pathway is also inhibited by dysfunctions in APP and apoE receptors (49–53). These findings therefore raise the intriguing possibility that perturbations in PI3K/Akt and/or MEK/ERK signaling may constitute common pathway(s) for neurodegeneration in both early and late onset AD.

Acknowledgments—We thank Dr. Gopal Thinakaran for the PSIN-PSC2 construct, Dr. Bart De Strooper for the PS-/- fibroblasts, Dr. Hiroshi Mori for the PSN2 antibody, Dr. Gloria Lee for Tau cDNA and antibodies (Tau-1 and Tau46), Dr. Peter Davies for the PHF1 antibody, and Dr. Hui Zheng for helpful discussion.

REFERENCES

1. Rogove, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., and Tsuda, T. (1995) Nature 376, 775–778
2. Sherrington, R., Rogoev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., and Holman, K. (1995) Nature 376, 754–769
3. Periz, G., and Fortini, M. E. (2004) J. Neurosci. Res. 77, 109–122
4. Levitan, D., and Greenwald, I. (1995) J. Neurosci. Res. 42, 508–518
5. Ye, Y., Lukinova, N., and Fortini, M. E. (1999) J. Biol. Chem. 274, 577–583
6. Steiner, H., Dufu, K., Capell, A., Komig, M., Lin, C., and De Strooper, B. (2004) J. Cell Biol. 165, 135–153
7. Iwatsubo, T., Thinakaran, G., and Koo, E. H. (2001) J. Biol. Chem. 276, 17136–17142
8. Pack-Chung, E., Meyers, M. B., Pettingell, W. M., Moir, R. D., Brownawell, A. M., Cheng, T., Tanzi, R., and Kim, W. (2004) J. Cell Biol. 164, 14440–14444
9. Stahler, S. M., Ostrowski, L. L., Janicki, S. M., and Monteiro, M. J. (1999) J. Cell Biol. 145, 1277–1292
10. Tanaka, K., and Harris, K. J. (2000) Hum. Mol. Genet. 9, 2281–2289
11. Fimia, G. M., De Cesare, D., and Sassone-Corsi, P. (2000) Mol. Cell. Biol. 20, 8613–8622
12. Labeurde, C., Renard, C. A., Neuroest, C., Buendia, M., and Wei, Y. (2004) Mol. Cell. Biol. 24, 10689–10702
13. Morlon, A., and Sassone-Corsi, P. (2003) Proc. Natl. Acad. Sci. USA 100, 3977–3982
14. Baki, L., Maramhdour, P., Efthimiopoulos, S., Georgakopoulou, A., Wen, P., Cui, W., Shioi, J., Koo, E., Ozawa, M., Friedrich, V. L., Jr., and Robakis, N. K. (2001) Proc. Natl. Acad. Sci. USA 98, 2381–2386
15. Wang, H., Luo, W., Zhang, Y. B., Li, Y. M., Thinakaran, G., Greengard, P., and Xu, H. (2004) Nature 430, 28669–28673
16. Beher, D., Wrige, J. D., Nadin, A., Evin, G., Masters, C. L., Harrison, T. C., Castro, L. J., and Shearnman, M. S. (2001) J. Biol. Chem. 276, 45394–45402
17. Muller, J. M., Isele, U., Metzger, K., Rempel, A., Massa, M., Pecherer, A., Breyer, T., Holubersch, C., Buettrig, R., and Schiele, R. (2000) EMBO J. 19, 359–369
18. Yang, Y., Hsu, H., Haller, E. M., Nicosia, S. V., and Bai, W. (2005) EMBO J. 24, 1021–1032
19. Uramoto, H., Wetskows, D., Hackzell, A., Matsumoto, Y., and Funa, K. (2004) J. Cell Sci. 117, 5323–5331
20. Thinakaran, G., Harris, C. L., Ratovitsi, T. Daveno, F., Slunt, F., Hult, P., Slunt, D., Borchelt, R., and Dinsor, S. S. (1997) J. Biol. Chem. 272, 28415–28422
21. Lee, M. K., Borchelt, R. D., Hult, P., Slunt, F., Hult, R., and Slunt, D. S. (1997) Nat. Med. 3, 756–760
22. Kaplan, D. R., and Miller, F. D. (1997) Curr. Opin. Cell Biol. 9, 213–221
23. Pang, Y., Wen, T., C., Ye, C., Ichihara, K., Osuda, H., and Sakakano, M. (1997) Neuron Res. 29, 335–343
24. Cheng, B., and Mattson, M. P. (1995) J. Neurosci. 15, 7095–7104
26. Simakomoroloss, N., Zippers, N., Gaoz, E., Monemeti, J. P., and Gaoz, D. (2001) Brain Res. Rev. 37, 111–118
27. Usnora, K., Kita, H., Kohna, R., Kuzuya, A., Kageyama, T., Chonabasiglio, J. (2003) J. Cell. Sci. 117, 5323–5331
28. Laffont, I., Takahashi, M., Shibayuta, Y., Honke, K., Shuevav, V. V., Sieg, G., Visvikis, S., and Taniguchi, N. (2002) Biochem. Biophys. Res. Commun. 293, 83–87
29. Beffert, U., Morfini, G., Bock, H. H., Reyna, H., Herd, S., and Herz, J. (2002) J. Biol. Chem. 277, 49958–49964
30. Hiesberger, T., Trommsdorff, M., Howell, B. W., Goffinet, A., Mummy, M. C., Cooper, D., and Herz, J. (1999) Neuron 24, 481–489
31. Kashour, T., Burton, T., Ishvrow, A., and Amara, F. M. (2003) Brain Res. 976, 1063–1075
32. Ryder, J. S., Yu, S., and Ni, B. (2004) Cell Signal. 16, 187–200
33. D. K. E. S., Y., S. Y., O., Repetto, T., Busse, N., Yernam, L. Y., and E. H. Koo (2004) Neurobiol. Aging 25, S559
Presenilins Mediate Phosphatidylinositol 3-Kinase/AKT and ERK Activation via Select Signaling Receptors: SELECTIVITY OF PS2 IN PLATELET-DERIVED GROWTH FACTOR SIGNALING

David E. Kang, Il Sang Yoon, Emanuela Repetto, Tracy Busse, Nader Yermian, Listya Ie and Edward H. Koo

J. Biol. Chem. 2005, 280:31537-31547.
doi: 10.1074/jbc.M500833200 originally published online July 13, 2005

Access the most updated version of this article at doi: 10.1074/jbc.M500833200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2005/07/27/M500833200.DC1

This article cites 54 references, 29 of which can be accessed free at
http://www.jbc.org/content/280/36/31537.full.html#ref-list-1